CEL-SCI is focused on finding the best way to activate the immune system to fight cancer, infectious and autoimmune diseases. We have a cancer immunotherapy drug in a Phase 3 clinical trial and a patented T-cell modulation platform technology (LEAPS) being utilized to develop antigen specific treatments in preclinical studies. We believe LEAPS may have the ability to reprogram a faulty immune system back to a more normal immune system and rheumatoid arthritis is the first indication. The lead LEAPS candidate, CEL-4000, is being developed under a $1.5 million grant from NIAMS of NIH for the treatment of RA. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient's immune system while it is still intact. Multikine, our lead investigational immunotherapeutic agent in a Phase 3 clinical trial, has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with SCCHN. CEL-SCI has operations in Vienna, VA and Baltimore, MD.